“
TL;DR
It concludes that while some drugs show beneficial outcomes in preclinical studies, clinical evidence is still limited.
Molecular Biology Reports · 6 authors, 7 centres
This summary was generated by AI from a single paper. It has not been reviewed by a clinician and is not clinical advice. Verify against the source before acting on it.
It concludes that while some drugs show beneficial outcomes in preclinical studies, clinical evidence is still limited.
This narrative review examines the anticancer properties of antiepileptic drugs, focusing on drugs that have shown positive results in clinical trials or preclinical studies. The authors highlight valproic acid, oxcarbazepine, lacosamide, lamotrigine, and levetiracetam as having potential beneficial outcomes against various cancers. The authors suggest that further clinical trials are needed and propose new pharmacological approaches for evaluation.